Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[Pt(NH3)2(IBgly)]NO3 is a **platinum(II) coordination complex** consisting of platinum bound to two ammine (NH3) ligands and one N-isobutylglycine (IBgly) ligand, with nitrate as a counterion. It is structurally related to the class of platinum(II) ammine complexes explored as anticancer agents, modeled after compounds like cisplatin. The IBgly ligand can modulate the compound's physicochemical properties such as solubility, stability, and potentially its biological activity or toxicity profile compared to more widely studied platinum-based drugs. The expected mechanism of action—by analogy with related platinum(II) coordination complexes—involves **binding to DNA, forming intrastrand and interstrand cross-links that interfere with DNA replication and transcription, ultimately leading to cell death**. Primary research indicates [Pt(NH3)2(IBgly)]NO3 is an experimental platinum compound and has been characterized by spectroscopic methods for evaluation as a possible anticancer candidate[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [Pt(NH3)2(IBgly)]NO3.